Why AIM ImmunoTech Inc. [AIM] Stock Can Charge Above The $1.95 Level

AIM ImmunoTech Inc. [AIM] stock is up 4.60 while the S&P 500 has risen 0.66% on Thursday, 12/03/20. While at the time of this article, AIM ATR is sitting at 0.11, with the beta value at -0.87. This stock’s volatility for the past week remained at 5.27%, while it was 5.04% for the past 30-day period. AIM has risen $0.09 from the previous closing price of $1.86 on volume of 1.15 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 25, November 2020, AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19. According to news published on Yahoo Finance, AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.39 and a peak of $7.11. Right now, the middling Wall Street analyst 12-month amount mark is $6.50. At the most recent market close, shares of AIM ImmunoTech Inc. [AMEX:AIM] were valued at $1.95.


AIM ImmunoTech Inc. [AMEX:AIM] most recently reported quarterly sales of 36.0 million, which represented growth of -41.00%. This publicly-traded organization’s revenue is $5,385 per employee, while its income is -$366,654 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -16.18, -105.45, -81.38 and -71.87 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 33.08 and the whole liability to whole assets at 10.02. It shows enduring liability to the whole principal at 31.77 and enduring liability to assets at 0.10 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.7867 points at 1st support level, the second support level is making up to 1.7133. But as of 1st resistance point, this stock is sitting at 1.9067 and at 1.9533 for 2nd resistance point.

AIM ImmunoTech Inc. [AIM] reported its earnings at -$0.08 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.08/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.11 calling estimates for -$0.1/share with the difference of -0.01 depicting the surprise of -10.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for AIM ImmunoTech Inc. [AMEX:AIM] is 50.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 7.79. Now if looking for a valuation of this stock’s amount to sales ratio it’s 14.15 and it’s amount to book ratio is 0.47.

Insider Stories

The most recent insider trade was by EQUELS THOMAS K., CEO & President, and it was the purchase of 12316.0 shares on Sep 03. EQUELS THOMAS K., the CEO, completed a purchase of 10730.0 shares on Aug 21.